Literature DB >> 8572635

The influence of obesity on the disease-free survival in primary breast cancer.

A Obermair1, C Kurz, E Hanzal, D Bancher-Todesca, M Thoma, A Bodisch, E Kubista, E Kyral, A Kaider, P Sevelda.   

Abstract

Hyper-estrogenism is more common in obese than in non-obese women. Consequently obesity has been shown to increase the risk of hormone department tumors. Some investigators have claimed that obesity at the time of primary treatment may be an independent prognostic factor for breast cancer, but this issue is still controversial. Therefore, we conducted a retrospective analysis to assess the influence of obesity at the time of primary treatment on disease-free survival (DFS). Obesity was defined as an excess of more than 25% of ideal weight according to Broca's index ([Height (cm) -100])-10%). The Cox-model was used for multivariate analysis. Mean follow-up was 61 (range 6-126) months. 295 (62.3%) patients were classified as of normal weight and 178 (37.6%) as obese. Mean excess of ideal weight was 8.9 kilograms (kg) in premenopausal and 13.9 kg in postmenopausal patients (non-parametric t-test p < 0.00001). Patients with tumor size < 20mm, 20-50mm and > 50mm had a means excess of the real weight of 10.6kg, 12.5kg and 16.1kg, respectively (non-parametric t-test p < 0.0001). Percentual excess of real weight compared to ideal weight was 22.4 [+/-21.2] kg in patients without recurrence and 21.5 [+/-21.9] in patients with recurrent disease (nonparametric t-test p = 0.7256). Univariate analysis revealed no significant association between obesity and the DFS. Multivariate analysis identified axillary lymph node involvement as the only statistically significant prognostic factor for disease-free survival (RR 1.55; 95%-confidence interval 1.02-2.36; p:0.0368). Because of the high correlations and node-status, tumor size and histological grading, the other factors failed to be prognostically relevant in this analysis. Obesity was not found to influence DFS of patients with primary breast cancer and is therefore unlikely to constitute an independent prognostic factor. It may, however, contribute to delayed diagnosis, since a significant proportion of obese patients were diagnosed with local advanced disease.

Entities:  

Mesh:

Year:  1995        PMID: 8572635

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  11 in total

Review 1.  Nutrition and survival after the diagnosis of breast cancer: a review of the evidence.

Authors:  Cheryl L Rock; Wendy Demark-Wahnefried
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

Review 2.  Obesity in cancer survival.

Authors:  Niyati Parekh; Urmila Chandran; Elisa V Bandera
Journal:  Annu Rev Nutr       Date:  2012-04-23       Impact factor: 11.848

3.  Obesity and survival among black women and white women 35 to 64 years of age at diagnosis with invasive breast cancer.

Authors:  Yani Lu; Huiyan Ma; Kathleen E Malone; Sandra A Norman; Jane Sullivan-Halley; Brian L Strom; Polly A Marchbanks; Robert Spirtas; Ronald T Burkman; Dennis Deapen; Suzanne G Folger; Michael S Simon; Michael F Press; Jill A McDonald; Leslie Bernstein
Journal:  J Clin Oncol       Date:  2011-07-25       Impact factor: 44.544

4.  Body mass index, tumor characteristics, and prognosis following diagnosis of early-stage breast cancer in a mammographically screened population.

Authors:  Aruna Kamineni; Melissa L Anderson; Emily White; Stephen H Taplin; Peggy Porter; Rachel Ballard-Barbash; Kathleen Malone; Diana S M Buist
Journal:  Cancer Causes Control       Date:  2012-12-07       Impact factor: 2.506

5.  Obesity and weight change in relation to breast cancer survival.

Authors:  Xiaoli Chen; Wei Lu; Wei Zheng; Kai Gu; Zhi Chen; Ying Zheng; Xiao Ou Shu
Journal:  Breast Cancer Res Treat       Date:  2010-01-08       Impact factor: 4.872

6.  Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity.

Authors:  John P Pierce; Marcia L Stefanick; Shirley W Flatt; Loki Natarajan; Barbara Sternfeld; Lisa Madlensky; Wael K Al-Delaimy; Cynthia A Thomson; Sheila Kealey; Richard Hajek; Barbara A Parker; Vicky A Newman; Bette Caan; Cheryl L Rock
Journal:  J Clin Oncol       Date:  2007-06-10       Impact factor: 44.544

7.  Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer.

Authors:  Jennifer K Litton; Ana M Gonzalez-Angulo; Carla L Warneke; Aman U Buzdar; Shu-Wan Kau; Melissa Bondy; Somdat Mahabir; Gabriel N Hortobagyi; Abenaa M Brewster
Journal:  J Clin Oncol       Date:  2008-09-01       Impact factor: 44.544

8.  Is obesity always a risk factor for all breast cancer patients? c-erbB2 expression is significantly lower in obese patients with early stage breast cancer.

Authors:  Umut Mousa; Handan Onur; Gungor Utkan
Journal:  Clin Transl Oncol       Date:  2012-07-25       Impact factor: 3.405

9.  Biomarkers of the metabolic syndrome and breast cancer prognosis.

Authors:  Qiu-Li Zhu; Wang-Hong Xu; Meng-Hua Tao
Journal:  Cancers (Basel)       Date:  2010-04-28       Impact factor: 6.639

10.  Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer.

Authors:  Takahiro Kogawa; Tamer M Fouad; Caimiao Wei; Hiroko Masuda; Kazuharu Kai; Takeo Fujii; Randa El-Zein; Mariana Chavez-MacGregor; Jennifer K Litton; Abenaa Brewster; Ricardo H Alvarez; Gabriel N Hortobagyi; Vicente Valero; Richard Theriault; Naoto T Ueno
Journal:  J Cancer       Date:  2015-01-22       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.